- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Matching IV Placebo, Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm
- Behavioral · Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 447
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Lung Injury
- Interventions
- Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis
- Drug · Other · Procedure
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 3
- States / cities
- Clackamas, Oregon • Portland, Oregon
- Conditions
- Arthroplasty, Replacement, Knee
- Interventions
- Pre Operative Oral Fluids
- Other
- Lead sponsor
- Colorado Joint Replacement
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Sickle Cell Disease, Vaso-occlusive Pain Episodes
- Interventions
- KindVR Aqua Program
- Device
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Palbociclib, Cetuximab, Cisplatin, Intensity-Modulated Radiation Therapy, Tumor biopsy, Peripheral blood draw
- Drug · Radiation · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions
- Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel, Prednisone
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 665
- States / cities
- Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 437 more
- Conditions
- POTS - Postural Orthostatic Tachycardia Syndrome
- Interventions
- Questionnaires to be competed, Provide list of medication and lifetime events, Use phone App to record new life events, Will wear an activity monitor, Periodic 24-hour urine sodium check, A fMRI scan, A bedside tilt test will be performed, IV placed to collect blood samples, Stool Sample
- Behavioral · Device · Other + 1 more
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 12 Years to 21 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Metastatic Breast Cancer
- Interventions
- Epicutaneous cryoimmunotherapy, Topical imiquimod, Pembrolizumab, Dermatologic Quality of Life Index, Functional Assessment of Cancer Therapy, Intra-lesional GM-CSF, Cry-AC, Cutaneous tumor biopsy, Peripheral blood draw for research
- Device · Drug · Other + 1 more
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Solid Tumor, Pancreatic Adenocarcinoma
- Interventions
- OBI-3424
- Drug
- Lead sponsor
- OBI Pharma, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 5
- States / cities
- La Jolla, California • Los Angeles, California • New Brunswick, New Jersey + 2 more
- Conditions
- Respiratory Distress Syndrome, Newborn
- Interventions
- Fluid Management Intervention
- Other
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- Up to 12 Hours
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- New York, New York • Lawton, Oklahoma
- Conditions
- Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Interventions
- Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide, Cyclosporine, Diagnostic Imaging, Echocardiography, Fludarabine Phosphate, Multigated Acquisition Scan, Mycophenolate Mofetil, Survey Administration, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 6 Months to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- COPD
- Interventions
- Zofin, Placebo
- Drug · Other
- Lead sponsor
- ZEO ScientifiX, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Cockayne Syndrome
- Interventions
- Prodarsan
- Drug
- Lead sponsor
- DNage B.V.
- Industry
- Eligibility
- 2 Years to 10 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hyponatremia
- Interventions
- lixivaptan, Placebo
- Drug
- Lead sponsor
- CardioKine Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 652 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 102
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Bakersfield, California + 82 more
- Conditions
- Rhabdomyosarcoma
- Interventions
- Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Radiation, Bevacizumab, Sorafenib, Myeloid Growth Factor, Lymph Node Sampling, Irinotecan, Ifosfamide, Etoposide, Etoposide Phosphate, Doxorubicin, Dexrazoxane, ^1^1C-methionine
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Memphis, Tennessee • Fort Worth, Texas
- Conditions
- Type1diabetes, Insulitis, Pancreas Inflamed
- Interventions
- Definity Suspension for Injection
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
- Interventions
- Arginine hydrochloride, Sodium Chloride 0.9%
- Drug
- Lead sponsor
- David K Carroll
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Biological · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm, Melanocytoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
- Procedure · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Periodontal Disease
- Interventions
- Investigational Procedure
- Procedure
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 226 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Iowa City, Iowa • Somerville, Massachusetts • Stony Brook, New York + 1 more
- Conditions
- Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
- Interventions
- [¹⁴C]Etelcalcetide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Leukemia
- Interventions
- filgrastim, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, mitoxantrone, Asparaginase, prednisone, thioguanine, vincristine, radiation therapy, allopurinol, bactrim
- Biological · Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 78
- States / cities
- Burbank, California • Maywood, Illinois • Chanute, Kansas + 45 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin
- Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 44 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- IBS (Irritable Bowel Syndrome)
- Interventions
- Inulin, Low-fiber control breakfast shake, Atmo Gas-Sensing Capsule, CapScan Regional Fluid-Sampling Capsule
- Dietary Supplement · Other · Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Stanford, California